関連する実験動画
まとめ
ドイツで使用されている認知症の薬であるメマンチン (Memantine) は,アルツハイマー病の治療に有望であることが示されています. 臨床試験では,中度重度のアルツハイマー病患者の症状進行を著しく遅らせることが示されています.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
背景:
- アルツハイマー病は進行性神経変性障害である.
- 現在のアルツハイマー病の治療法は限られており,β-アミロイドワクチンのような新しい治療法に関する研究が進行中です.
- メマンタインは,ドイツで認知症の治療に10年以上の使用歴があります.
研究 の 目的:
- アルツハイマー病の症状の進行を遅らせるメマンタインの有効性を評価する.
- 伝統的なアルツハイマー病の治療法としてのメマンチンの可能性に関する発見を提示する.
主な方法:
- メマンチンのアルツハイマー病患者への影響を評価するために臨床試験が行われました.
- この研究は,中度重度のアルツハイマー病を患っている患者に焦点を当てました.
主要な成果:
- メマンチンは,中度重症の患者のアルツハイマー病の症状の進行を著しく遅らせました.
- 研究結果は2000年世界アルツハイマー病会議で発表されました.
結論:
- メマンチンは,アルツハイマー病の治療薬としての潜在能力を示しています.
- この従来の薬は,アルツハイマー病の新興治療への有望な代替品または補助剤を提供します.
関連する概念動画
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.